Regulatory consequences of “Brexit” for the development of medicinal products
Jackson, E.
, Feldschreiber, P. & Breckenridge, A.
(2017).
Regulatory consequences of “Brexit” for the development of medicinal products.
Clinical Pharmacology and Therapeutics,
102, 183-184.
https://doi.org/10.1002/cpt.706
, Feldschreiber, P. & Breckenridge, A.
(2017).
Regulatory consequences of “Brexit” for the development of medicinal products.
Clinical Pharmacology and Therapeutics,
102, 183-184.
https://doi.org/10.1002/cpt.706
The United Kingdom voted in a referendum in June 2016 to leave the European Union (EU) after 45 years of membership. Among the many political, social, and scientific consequences are those for the regulation of health care products. No longer will the efficacy, safety, and quality of medicines in the United Kingdom be subject to an EU regulatory framework. The European Medicines Agency (EMA), which is currently located in London, will move elsewhere in Europe. The pharmaceutical industry will reassess its commitment to the UK health scene.